Dicyclomine Dosing for Pediatric Patients
Dicyclomine is contraindicated in infants less than 6 months of age due to potential serious adverse effects including respiratory symptoms, seizures, syncope, and death. 1
Safety Concerns and Contraindications
- Dicyclomine is explicitly contraindicated in infants under 6 months of age according to FDA labeling 1
- Serious adverse events reported in infants include:
- Respiratory symptoms (dyspnea, shortness of breath, respiratory collapse, apnea)
- Neurological effects (seizures, syncope, coma)
- Cardiovascular effects (pulse rate fluctuations)
- Muscular hypotonia
- Death
Dosing Recommendations for Children Over 6 Months
For children over 6 months where dicyclomine is deemed necessary:
Dosing for Infantile Colic (off-label use):
- 3 mg/kg/day divided into multiple doses 2
This dosage has been studied specifically for infantile colic in infants aged 3-12 weeks, though it's important to note that current guidelines no longer recommend dicyclomine for this indication due to safety concerns.
Important Clinical Considerations:
Alternative Treatments: For infantile colic, dietary modifications have shown better efficacy than dicyclomine (95.4% vs 53.3% improvement) 2
Monitoring: When dicyclomine must be used in children over 6 months:
- Monitor for respiratory symptoms
- Watch for neurological changes
- Assess for cardiovascular effects
- Evaluate for muscular hypotonia
Drug Interactions: Be aware of potential interactions, particularly with diuretics like HCTZ which can lead to contraction alkalosis 3
Pediatric Pharmacokinetic Considerations
Pediatric patients require individualized dosing based on:
- Age
- Size
- Organ maturity level
Children are not simply "small adults" and require careful dose calculations to optimize efficacy while preventing serious adverse effects 4.
Clinical Recommendation
For children over 6 months where dicyclomine is absolutely necessary, use 3 mg/kg/day divided into multiple doses, but strongly consider safer therapeutic alternatives given the significant safety concerns with this medication in the pediatric population. 1, 2
The absence of FDA approval for pediatric use and the explicit contraindication in infants under 6 months should prompt extreme caution when considering this medication in any pediatric patient.